- Home
- EXEL vs BSAC Comparison
EXEL vs BSAC Comparison
Compare EXEL & BSAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXEL
- BSAC
- Stock Information
- Founded
- EXEL 1994
- BSAC 1977
- Country
- EXEL United States
- BSAC Chile
- Employees
- EXEL N/A
- BSAC N/A
- Industry
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- BSAC Commercial Banks
- Sector
- EXEL Health Care
- BSAC Finance
- Exchange
- EXEL Nasdaq
- BSAC Nasdaq
- Market Cap
- EXEL 11.3B
- BSAC 11.5B
- IPO Year
- EXEL 2000
- BSAC 1994
- Fundamental
- Price
- EXEL $44.08
- BSAC $25.20
- Analyst Decision
- EXEL Buy
- BSAC Hold
- Analyst Count
- EXEL 18
- BSAC 3
- Target Price
- EXEL $43.00
- BSAC $22.00
- AVG Volume (30 Days)
- EXEL 3.3M
- BSAC 476.6K
- Earning Date
- EXEL 08-05-2025
- BSAC 07-30-2025
- Dividend Yield
- EXEL N/A
- BSAC 3.94%
- EPS Growth
- EXEL 237.58
- BSAC 111.01
- EPS
- EXEL 2.20
- BSAC 0.01
- Revenue
- EXEL $2,298,922,000.00
- BSAC $2,379,764,303.00
- Revenue This Year
- EXEL $9.37
- BSAC $39.42
- Revenue Next Year
- EXEL $11.05
- BSAC $5.73
- P/E Ratio
- EXEL $19.98
- BSAC $10.99
- Revenue Growth
- EXEL 24.49
- BSAC 49.00
- 52 Week Low
- EXEL $21.82
- BSAC $18.19
- 52 Week High
- EXEL $49.62
- BSAC $25.53
- Technical
- Relative Strength Index (RSI)
- EXEL 57.96
- BSAC 52.82
- Support Level
- EXEL $42.66
- BSAC $24.43
- Resistance Level
- EXEL $49.62
- BSAC $24.90
- Average True Range (ATR)
- EXEL 1.58
- BSAC 0.49
- MACD
- EXEL 0.10
- BSAC -0.01
- Stochastic Oscillator
- EXEL 43.24
- BSAC 58.61
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About BSAC Banco Santander - Chile ADS
Founded in 1978, Banco Santander Chile is part of Santander Group and majority-controlled by Santander Spain. It is the largest bank in Chile by loans and the second largest by deposits. The bank generates most of its net interest income (roughly 65% of total revenue) from its mortgages, unsecured consumer credit lines, and commercial loans. Banco Santander's commercial loan business is more focused on small- to medium-size companies, with firms generating more than CLP 10,000 million in revenue only making up around 5% of outstanding loans. Outside of lending, Banco Santander is the largest card issuer in the country with around 25% of the market and benefits from a long-term strategic partnership with the largest airline in the country, LATAM.